Daniel C. St. Louis
Henry M. Jackson Foundation for the Advancement of Military Medicine
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Daniel C. St. Louis.
Science | 1996
Bruce L. Levine; Joseph D. Mosca; James L. Riley; Richard G. Carroll; Maryanne Vahey; Linda L. Jagodzinski; Kenneth F. Wagner; Douglas L. Mayers; Donald S. Burke; Owen S. Weislow; Daniel C. St. Louis; Carl H. June
Because stimulation of CD4+ lymphocytes leads to activation of human immunodeficiency virus-type 1 (HIV-1) replication, viral spread, and cell death, adoptive CD4+ T cell therapy has not been possible. When antigen and CD28 receptors on cultured T cells were stimulated by monoclonal antibodies (mAbs) to CD3 and CD28 that had been immobilized, there was an increase in the number of polyclonal CD4+ T cells from HIV-infected donors. Activated cells predominantly secreted cytokines associated with T helper cell type 1 function. The HIV-1 viral load declined in the absence of antiretroviral agents. Moreover, CD28 stimulation of CD4+ T cells from uninfected donors rendered these cells highly resistant to HIV-1 infection. Immobilization of CD28 mAb was crucial to the development of HIV resistance, as cells stimulated with soluble CD28 mAb were highly susceptible to HIV infection. The CD28-mediated antiviral effect occurred early in the viral life cycle, before HIV-1 DNA integration. These data may facilitate immune reconstitution and gene therapy approaches in persons with HIV infection.
Journal of Clinical Immunology | 1997
Patrick J. Blair; Lawrence H. Boise; Stephen P. Perfetto; Bruce L. Levine; Gil McCrary; Kenneth F. Wagner; Daniel C. St. Louis; Craig B. Thompson; Jeffrey N. Siegel; Carl H. June
Progression to AIDS in asymptomatic HIV-infected individuals is characterized by a gradual but progressive loss of CD4+ T cells. While the mechanisms underlying this decline are currently unknown, recent evidence suggests that these cells are abnormally sensitive to apoptosis in response to activation signals. Recent work has implicated downregulation of Bcl-2 with the increased spontaneous apoptosis in lymphocytes from HIV-infected patients. We have evaluated the roles of the apoptosis-protective proteins Bcl-2 and Bcl-x in stimulated PBMC from asymptomatic HIV-infected and HIV-uninfected individuals. We found that Bcl-2 was constitutively expressed in PBMC from both HIV-infected and uninfected samples. However, Bcl-x induction was delayed and responses were decreased in stimulated HIV-infected samples. Additionally, single-cell intracellular staining of Bcl-x revealed a significant inverse correlation between PWM-induced Bcl-x expression and apoptosis (r = −0.695, P = 0.005). This was confirmed at the single-cell level in direct experiments when stimulated cells were sorted based on Bcl-x induction and then measured for apoptosis. Furthermore, low Bcl-x expression was not due to reduced lymphocyte activation following PWM stimulation. Our data indicate that the induction of Bcl-x is markedly impaired in asymptomatic HIV-infected patients and that stimuli which induce inadequate expression of Bcl-x are associated with increased levels of apoptosis in these cells.
Human Gene Therapy | 2000
John P. Chute; Abha Saini; Mark Wells; William Clark; Andrea Wu; Daniel C. St. Louis; Patrick J. Blair; David M. Harlan; Sumesh Kaushal
Retroviral gene transfer studies targeting bone marrow CD34(+)CD38(-) stem cells have been disappointing because of the rarity of these cells, their G(0) cell cycle status, and their low or absent expression of surface retroviral receptors. In this study, we examined whether preincubation of bone marrow CD34(+)CD38(-) stem cells with a hematopoietically supportive porcine microvascular endothelial cell line (PMVECs) could impact the cell cycle status and expression of retroviral receptors in pluripotent CD34+CD38- cells and the efficiency of gene transfer into these primitive target cells. PMVEC coculture supplemented with GM-CSF + IL-3 + IL-6 + SCF + Flt-3 ligand induced >93% of the CD34(+)CD38(-) population to enter the G(1) or G(2)/S/M phase while increasing this population from 1.4% on day 0 to 6.5% of the total population by day 5. Liquid cultures supplemented with the identical cytokines induced 73% of the CD34(+)CD38(-) population into cell cycle but did not maintain cells with the CD34(+)CD38(-) phenotype over time. We found no significant increase in the levels of AmphoR or GaLVR mRNA in PMVEC-expanded CD34(+)CD38(-) cells after coculture. Despite this, the efficiency of gene transfer using either amphotropic vector (PA317) or GaLV vector (PG13) was significantly greater in PMVEC-expanded CD34(+)CD38(-) cells (11.4 +/- 5.6 and 10.9 +/- 5.2%, respectively) than in either steady state bone marrow CD34(+)CD38(-) cells (0.6 +/- 1.7 and 0.2 +/- 0.6%, respectively; p < 0.01 and p < 0.01) or liquid culture-expanded CD34(+)CD38(-) cells (1.4 +/- 3.5 and 0.0%, respectively; p < 0.01 and p < 0.01). Since PMVEC coculture induces a high level of cell cycling in human bone marrow CD34(+)CD38(-) cells and expands hematopoietic cells capable of in vivo repopulation, this system offers potential advantages for application in clinical gene therapy protocols.
Journal of Biomedical Science | 1995
Joseph D. Mosca; Sumesh Kaushal; Suzanne Gartner; Stephen W. Kessler; Vince F. La Russa; Ernest F. Terwilliger; Jerome H. Kim; Richard G. Carroll; Eric R. Hall; Liyanage P. Perera; Zhipeng Yu; David W. Ritchey; Jin Xu; Daniel C. St. Louis; Douglas L. Mayers
Our objective was to determine the role that bone marrow-derived stromal cells have on human hematopoiesis in HIV infection. In particular, we dissected the heterogeneous bone marrow microenvironment to study the effect HIV expression might have on the cell population capable of producing the cytokines which will support human CD34+ cell differentiation. A stromal cell line, Lof(11-10), was established from human bone marrow by transfecting a plasmid containing the SV40 large T-antigen and isolating foci exhibiting a transformed phenotype. The Lof(11-10) cell line was characterized to determine its susceptibility to HIV infection, to identify its cytokine production profile, and to test the ability of conditioned media from this line to support CD34+ cell differentiation in the presence and absence of HIV expression. Nine cytokines were detected by RT-PCR and ELISA analysis. Conditioned media obtained from the Lof(11-10) cell line was able to support CD34+ celle differentiation. However, because the Lof(11-10) cells are not infectible by HIV, molecular clones of HIV were introduced into these cells by transfection. There was no qualitative difference in the levels of cytokine production between HIV-expressing and control Lof(11-10) cells. Furthermore, conditioned media derived from HIV-expressing and control Lof(11-10) cells added to bone marrow-derived CD34+ progenitor cells yielded similar colony formation in methylcellulose assays. Our data suggest that HIV infection of the cytokine-producing cells within the bone marrow microenvironment, as represented by the Lof(11-10) cell line, results in both normal cytokine production and hematopoiesis in spite of HIV expression. This report adds to the evidence against stromal cells being a significant target of HIV and establishes a system for comparison with more relevant models. Copyright 1995 S. Karger AG, Basel
Science | 1997
Richard G. Carroll; James L. Riley; Bruce L. Levine; Yu Feng; Sumesh Kaushal; David W. Ritchey; Wendy B. Bernstein; Owen S. Weislow; Charles R. Brown; Edward A. Berger; Carl H. June; Daniel C. St. Louis
Journal of Immunology | 1999
Daniel C. St. Louis; Juliana B. Woodcock; Guido Fransozo; Patrick J. Blair; Louise M. Carlson; Maria Murillo; Mark Wells; Amanda J. Williams; Douglas S. Smoot; Sumesh Kaushal; Janelle L. Grimes; David M. Harlan; John P. Chute; Carl H. June; Ulrich Siebenlist; Kelvin P. Lee
Journal of Virology | 1998
Daniel C. St. Louis; Deanna Gotte; Eric Sanders-Buell; David W. Ritchey; Mika Salminen; Jean K. Carr; Francine E. McCutchan
Journal of Immunology | 1998
James H. Horspool; Peter J. Perrin; Juliana B. Woodcock; Josephine H. Cox; Christopher L. King; Carl H. June; David M. Harlan; Daniel C. St. Louis; Kelvin P. Lee
Clinical Immunology | 1999
Sumesh Kaushal; Alan Landay; Michael M. Lederman; Elizabeth Connick; John Spritzler; Daniel R. Kuritzkes; Harold A. Kessler; Bruce L. Levine; Daniel C. St. Louis; Carl H. June
Seminars in Immunology | 1998
Richard G. Carroll; James L. Riley; Bruce L. Levine; Patrick J. Blair; Daniel C. St. Louis; Carl H. June
Collaboration
Dive into the Daniel C. St. Louis's collaboration.
Henry M. Jackson Foundation for the Advancement of Military Medicine
View shared research outputsHenry M. Jackson Foundation for the Advancement of Military Medicine
View shared research outputsHenry M. Jackson Foundation for the Advancement of Military Medicine
View shared research outputs